You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Details for New Drug Application (NDA): 202344

✉ Email this page to a colleague

« Back to Dashboard

NDA 202344 describes BINOSTO, which is a drug marketed by Radius and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the BINOSTO profile page.

The generic ingredient in BINOSTO is alendronate sodium. There are twenty-five drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.

Summary for 202344

Tradename:	BINOSTO
Applicant:	Radius
Ingredient:	alendronate sodium
Patents:	1
Formulation / Manufacturing:	see details

Pharmacology for NDA: 202344

Medical Subject Heading (MeSH) Categories for 202344

Bone Density Conservation Agents

Suppliers and Packaging for NDA: 202344

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344	NDA	ASCEND Therapeutics	17139-400	17139-400-01	1 TABLET, EFFERVESCENT in 1 CARTON (17139-400-01)
BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344	NDA	ASCEND Therapeutics	17139-400	17139-400-04	4 TABLET, EFFERVESCENT in 1 CARTON (17139-400-04)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, EFFERVESCENT;ORAL			Strength	EQ 70MG BASE
Approval Date:	Mar 12, 2012	TE:		RLD:	Yes
Patent:	⤷ Try a Trial	Patent Expiration:	Dec 5, 2031	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 202344

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Radius	BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344-001	Mar 12, 2012	⤷ Try a Trial	⤷ Try a Trial
Radius	BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344-001	Mar 12, 2012	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.